Alterity participates in world’s largest virtual healthcare conference JP Morgan
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler will meet with investors during the JP Morgan Healthcare conference, which will run virtually this year from 11th-15th January 2021.
Dr Stamler, who was recently appointed CEO of Alterity, is presenting at the HC Wainwright BioConnect and Biotech Showcase events. Both events are popular satellite conferences held during the JP Morgan healthcare conference. This year the events will be held virtually, however in previous years more than 30,000 company executives and investors attend various healthcare and life science events in San Francisco in the second week of January.
Dr Stamler is a seasoned life science leader who prior to the CEO role was Alterity’s Chief Medical Officer and Senior Vice President Clinical Development. He joined Alterity having successfully commercialised three neurodegenerative disease treatments in his role as Chief Medical Officer of Auspex, which were approved by the US FDA. His succession to CEO supports the company’s advancement of its lead drug candidate ATH434 which has completed phase 1 clinical trials in its first disease indication Multiple System Atrophy, a type of Parkinsonian disease.
Dr Stamler will present:
- The progress of the company’s lead compound ATH434 for the treatment of Multiple System Atrophy (MSA) which has successfully completed a phase 1 clinical trial;
- The initiation of a Natural History Study at Vanderbilt University Hospital in the US which will provide important data to inform the phase 2 clinical study;
- The expected commercialisation pathway for ATH434; and
- The underlying science.
Investors can access Dr Stamler’s presentation for the HC Wainwright conference here from 11 January 2021 6:00 am (EST) / 10pm (ADST).
Authorization & Additional information
This announcement was authorized by Geoffrey Kempler, Chairman of Alterity Therapeutics Limited.